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A generic strategy for pharmacological caging of
growth factors for tissue engineering†
Maria Karlsson,ab Philipp S. Lienemann,cd Natallia Sprossmann,ae
Katharina Heilmann,f Tilman Brummer,efg Matthias P. Lutolf,d Martin Ehrbarc and
Wilfried Weber*abef
The caging of small molecules has revolutionized biological research
by providing a means to regulate a wide range of processes. Here we
report on a generic pharmacological method to cage proteins in a
similar fashion. The present approach is of value in both fundamental
and applied research, e.g. in tissue engineering.
The trapping of biological compounds in cages and the subsequent
controlled uncaging of them at the site of interest allows for a nearly
instantaneousmanipulation of the bioactive compound concentration.
The caging of small signaling molecules, such as second messengers
(e.g. calcium and inositol triphosphate),1,2 neurotransmitters (e.g. glu-
tamate),3 and nucleotides (e.g. ATP and ADP),4,5 has revolutionized
biological research by providing a means to spatiotemporally regulate
and monitor a wide range of cellular processes. Caging based on
chemical modification of the molecule using a photo-removable
protective group has been successfully applied to a multitude of small
signaling molecules. The same strategy has also been applied to
chemically synthesizable peptides,6,7 however, it is in most cases not
compatible with large proteins. Instead, large proteins require a tailored
caging procedure for each individual protein of interest, and the caging
is often complicated due to diﬃculties in achieving site-specific
chemical modification. Considering the wide range of biological
signaling processes relying on non-chemically synthesizable proteins,
there is a demand for a method enabling the caging of these in a
generic manner. Such a method would be an excellent tool for the
manipulation of protein-regulated processes, e.g. in developmental
biology and tissue engineering. In order to realize this, two separate
parts are required: a cage able to trap any protein of choice, and a
generically applicable protocol for producing cage-compatible cargo
proteins with high yield.
We have developed a generic system enabling pharmacological
caging and uncaging of arbitrary proteins equipped with an immu-
noglobulin (IgG) Fc-tag. The cage was formed by covalently coupling
novobiocin to an epoxy-activated agarose matrix via a nucleophilic
addition reaction. The anchoring of the cargo protein to the cage was
realized using an adaptor protein consisting of the novobiocin-
binding domain of the bacterial protein gyrase subunit B (GyrB)
fused to the IgG-binding domain ZZ derived from Staphylococcus
aureus protein A (Fig. 1a). The adaptor protein binds to the novobiocin
on the cage through its GyrB domain, allowing the ZZ-domain of
the adaptor protein to anchor the cargo protein by binding to the
Fc-domain. Upon the administration of free novobiocin at pharmaco-
logically relevant concentrations, binding between the adaptor protein
and the cage is competitively inhibited, which results in the uncaging of
the cargo protein. The rapid uncaging of the protein produces a step
function-like release of the bioactive compound, which enables precise
temporal regulation of the target process (Fig. 1a).
The cage was characterized in cell culture medium using an
Fc-tagged versionof thehumanplacental secreted alkalinephosphatase
(SEAPFc) as a humanmodel glycoprotein. Caged SEAPFc was incubated
with various concentrations of novobiocin and the amount of uncaged
SEAPFc was monitored by measuring the enzymatic activity of the
protein over a time period of 5 hours (Fig. 1b). Without novobiocin,
only a low level of unspecific uncaging occurs. The addition of
novobiocin, either immediately or after two hours, triggered rapid
uncaging of the protein. The final activity depended on the novobiocin
concentration. A maximum uncaged protein fraction of 70% was
measured at novobiocin concentrations equal to or greater than
60 mM. The caging eﬃciency was determined to be 35 ng of SEAPFc
per mg of the cage, of which 4.2% are non-specifically adsorbed.
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Growth factor-controlled processes are of fundamental importance
in both developmental biology and tissue engineering. One out of the
many potential applications of our generic system is the caging of
growth factors, which would enable the regulation and thus analysis
and engineering of the numerous signaling processes governed by
these proteins. To achieve this aim a production protocol applicable
to awide range of growth factors is required in addition to the cage. In
order to eﬃciently engineer an arbitrary growth factor for incorpora-
tion into the cage, we devised a generic gene assembly and protein
production platform (see ESI†). The growth factor platform was
validated for the manufacturing of cage-compatible variants of the
vascular endothelial growth factor 121 (VEGFFc), the insulin-like
growth factor 1 (IGF1Fc), and the platelet-derived growth factor
subunit B (PDGF-BBFc), resulting in a protein yield of 950 ng ml
1,
1170 ng ml1 and 400 ng ml1, respectively. Although the protein
expression protocol was not explicitly optimized for each of the growth
factors, the production yield was significantly improved for all of
them (ESI,† Fig. S1c). This suggests that the optimized production
protocol can be generally applied to increase the expression yield
of cage-compatible Fc-tagged recombinant proteins.
In order to ensure that the growth factors remain bioactive when
equipped with an Fc-tag, bioactivity assays for all produced growth
factors were performed. The bioactivity of VEGFFc was confirmed by
assessing the VEGFFc-induced proliferation of human umbilical vein
endothelial cells (HUVECs, Fig. 2a, ref. 8). The bioactivity of IGF1Fc
was evaluated by stimulating mouse embryonic fibroblasts (MEFs)
with 50 ng ml1 IGF1Fc during various time periods resulting in
pathway activation as demonstrated by the phosphorylation of ERK
and AKT as well as the induction of the immediate early gene
product Egr-1 (Fig. 2b, ref. 9 and 10). The bioactivity of PDGF-BBFc
was demonstrated using human embryonic kidney cells (HEK-293T)
transiently transfected with a PDGF-signaling based luciferase repor-
ter system (Fig. 2c). The observation that all three Fc-engineered
growth factors showed bioactivity is in line with previous studies
showing that commercially available Fc-tagged proteins represent a
highly valuable research tool.11,12 In order to analyze whether the
adaptor protein changes the binding to the receptor we determined
the relative receptor binding aﬃnities of the Fc-engineered growth
factors as a function of GyrB-ZZ (ESI,† Fig. S2a–c). As observed
from the Scatchard plots, the maximum specific binding and
the dissociation constant are comparable for the adaptor-bound
and free Fc-growth factors. The recombinant factors without the
Fc-tag showed different activity compared to the Fc variants, a
factor that is commonly taken into account when working with
commercial Fc-tagged growth factors.13
Following the successful development of the cage and the
establishment of an optimized generic protocol for the produc-
tion of cage-compatible growth factors, the two were combined
to explore the potential to regulate cellular signaling pathways in
cell culture by the conditional uncaging of growth factors. For
this purpose, caged PDGF-BBFc was added to HEK-293T cells
engineered with the PDGF signaling pathway coupled to firefly
luciferase. Fig. 3a shows the concentration of uncaged protein
and the normalized firefly luciferase activity for cells harvested 7,
14, or 21 hours post-transfection, cultivated in the absence or
presence of novobiocin. The addition of novobiocin resulted in a
thirty-fold increased activity for all incubation times investigated,
indicating uncaging of bioactive protein and subsequent activa-
tion of the PDGF signaling pathway. Cells cultivated in the
absence of novobiocin showed a similar activity level to the
control cells without a cage, showing that the caged growth
Fig. 1 Design and characterization of the cage. (a) Schematic representation of the
cage. The cage is synthesized by covalently functionalizing a mesh-like epoxy-activated
agarose resin with novobiocin. An adaptor protein constructed from novobiocin-binding
GyrB and the Fc-binding minimal protein A-derived ZZ domain is used to cage an Fc-
containing target protein. The administration of free novobiocin competitively inhibits the
binding between the adaptor protein and the cage, resulting in uncaging of the cargo
protein and regulation of the target process. (b) Dose-dependent uncaging kinetics in cell
culturemedium. Caged SEAPFc (8mg cage per 5ml) was incubated in DMEM cell culture
medium in the presence of various concentrations of novobiocin added immediately or
after 2 hours. The activity of uncaged SEAPFc was determined in the supernatant at the
indicated time points. Error bars represent one standard deviation of three experiments.
Fig. 2 Validation of growth factor bioactivity. (a) Bioactivity of cageable VEGFFc. HUVECs
were incubated for 96 h in the presence of the indicated VEGFFc concentrations prior to
quantification of proliferation using the WST-1 assay. Data indicate the mean and the
standard deviation of triplicate experiments. (b) Bioactivity of cageable IGF1Fc. MEFs were
stimulated with 50 ng ml1 IGF1Fc for the indicated time periods and the target proteins
were detected via western blotting using the indicated antibodies. Anti-pERK; dual
phosphorylated extracellular signal regulated kinase, anti-pAKT S473; phospho-Akt
(Ser473), anti-Egr-1; early growth response protein 1. (c) Bioactivity of cageable
PDGF-BBFc. HEK-293T cells were co-transfected with the plasmids for the PDGF signaling
pathway coupled to a firefly luciferase output promoter (PDGF-BB receptor, pPDGFR-BB;
GAL4-Elk1 fusion protein, pFA2-Elk1; GAL4-responsive firefly luciferase reporter, pFR-Luc).
As an internal control, the constitutive renilla luciferase expression vector (pGL4.75) was
included in the transfection mix. The cells were incubated for 48 h in the presence of
the indicated PDGF-BBFc concentrations prior to quantification of luciferase activity. The
PDGF-responsive firefly luciferase activity was normalized to the renilla luciferase activity.
Data indicate the mean and the standard deviation of triplicate experiments.
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factor did not influence the cellular behavior and that any non-
specific leakage from the cage is negligible (Fig. 3a).
Systems using growth factor concentration gradients to
control the migration of mesenchymal progenitor cells (MSCs)
are important in the development of cell- and gene-based anti-
tumor therapies. MSCs are known to migrate toward inflamed
sites14 and have therefore been considered as potential delivery
vehicles for the treatment of many diseases, for example
cancer.15–17 The combination of our cage with MSCs assembled
into microtissues enables time-resolved regulation of MSC
migration in three dimensions under in vivo-like conditions.
For this purpose, microtissues assembled from MSCs were
embedded into a metalloprotease-sensitive polyethylene glycol-
based hydrogel18 and cultivated together with the cage harboring
trapped PDGF-BBFc. Controlled uncaging of the protein by the
addition of novobiocin allows the uncaged PDGF-BBFc to bind to its
cognate extracellular receptor on the MSCs, thereby stimulating the
three-dimensional migration of the cells. Fig. 3b shows microscope
images of theMSCs and Fig. 3c shows the total number ofmigrated
cells after 16 hours of cultivation together with the cage containing
trapped PDGF-BBFc in the absence or presence of novobiocin.
A movie illustrating the eﬀect of uncaged PDGF-BBFc on the
migration of MSCs can be found in the ESI† (Video S1).
We have demonstrated a generic approach for the caging and
uncaging of arbitrary proteins. The cage along with optimized growth
factor production provides a versatile platform for exploring a variety
of biological signaling processes through the precisely controlled
uncaging of a bioactive compound. The controlledmigration ofMSCs
through regulated uncaging of growth factors illustrates how our
system can be used to precisely direct cellular behavior. Considering
the tremendous success of caged small signaling molecules in
biological research, we believe that the present method will be a
valuable asset, not only in developmental biology, tissue engineering
and anti-tumor therapy, where the understanding and manipulation
of growth factor-controlled signaling processes is of fundamental
importance, but also for the regulation of a wide range of additional
biological processes of interest in fundamental and applied research.
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Fig. 3 Inducible uncaging of PDGF-BBFc for stimulating MSC mobilization. (a) Unca-
ging of PDGF-BBFc in cell culture for controlled cell stimulation. Caged PDGF-BBFc
(16 mg cage per ml) was incubated together with HEK-293T cells transfected with the
luciferase-based PDGF reporter system (see Fig. 2c) and cultivated in the presence
(6 mM) or absence of novobiocin for the indicated time periods prior to quantifying the
luciferase activity and the concentration of uncaged PDGF-BBFc. Data indicate themean
and the standard deviation of triplicate experiments. The solid and dashed lines
represent the normalized luciferase activity and the PDGF-BBFc concentration, respec-
tively. (b) Mobilization of MSCs by inducible growth factor uncaging. Microtissues
assembled from MSCs (750 cells) were incorporated into a metalloprotease-sensitive
polyethylene glycol-based hydrogel (gel volume: 20 ml) together with caged PDGF-BBFc
(40 mg cage). The hydrogels were incubated in cell culture medium in the presence
(6 mM) or absence of novobiocin for 16 h. Cell migration was monitored by time-lapse
microscopy (see ESI†). Lightmicroscope images of representative spheroids after 16 h of
incubation are shown. (c) Quantification of MSC mobilization. The cells (Fig. 3b) were
fixed and stained with DAPI and the total number of migrated cells was determined.
The data represent the mean and SEM of three experiments, the asterisk indicates a
statistically significant diﬀerence to the control with po 0.05.
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